Asian NSCLC patients (but not Caucasian NSCLC patients) bearing the favorable GSTP1 IIe105Val + Val105Val genotypes were more likely to have better response rates to platinum-based chemotherapy compared to those with the unfavorable IIe105IIe genotype. The gene discussed is GSTP1; the disease is non-small cell lung carcinoma.